Article

Visiogen forms European subsidiary, releases accommodating IOL

During the winter meeting of the European Society of Cataract and Refractive Surgeons, held in early February here, Visiogen Inc. announced the formation of its European subsidiary, Visiogen Europe.

Rome

-During the winter meeting of the European Society of Cataract and Refractive Surgeons, held in early February here, Visiogen Inc. announced the formation of its European subsidiary, Visiogen Europe. Visiogen also announced that it will begin the controlled commercial release of its proprietary accommodating IOL (Synchrony) in Europe.

Visiogen was founded in Irvine, CA, in 2001. More than 1,000 of the accommodating lenses have been implanted in clinical trials.

During this recent ESCRS meeting, results from clinical research on the Synchrony dual optic accommodating IOL were featured in seven presentations and two posters. These included the initial results from new randomized, controlled European trials that compared the lens with an aspheric lens (AcrySof ReSTOR Aspheric, Alcon Laboratories) and a multifocal lens (Tecnis, Advanced Medical Optics), in which the accommodating IOL compared favorably. Results from a study from the University of Heidelberg showed objective dynamic accommodation with the accommodating lens at 5 years post-implantation.

“We are pleased with the growing interest in the [accommodating] IOL in Europe and the positive European clinical results that were presented in Rome,” said Stuart Windsor, managing director of Visiogen Europe, in a prepared statement. “The establishment of a permanent Visiogen presence in Europe is evidence of our commitment to supporting our European customers and to commercializing this exciting technology in a safe and responsible manner.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.